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Abstract
Introduction: Asthma diagnosis in young children may represent a clinical challenge. There are no standard prognostic and dia-
gnostic methods. The aim of the study was to evaluate the clinical and prognostic assessment of IL-4 and IL-13 concentrations 
in children with recurrent wheezing.
Material and methods: The study included 96 children with recurrent wheezing. 81 patients were diagnosed as transient 
wheezing, 15 patients with asthma, and 25 healthy children were selected as controls. The concentrations of IL-4 and IL-13 were 
analyzed in exhaled breath condensate (EBC) using an enzyme-linked immunosorbent assay (ELISA). Data analysis was performed 
using Statsoft Statistica Version 8 (Tulsa, OK) and the statistical program MedCalc version 17.2.
Results: Both IL-4 and IL-13 concentrations were significantly higher in DDA (21.13 pg/mL, 26.13 pg/mL, respectively) and 
TW (13.86 pg/mL, 18.3 pg/mL, respectively) groups as compared to healthy controls (3.37 pg/mL, 16.35 pg/mL, respectively; 
p < 0.001), and the highest rates were observed in children with diagnosed asthma (p < 0.001, DDW vs TW, respectively). IL-4 
concentration higher than 18.45 pg/mL (with sensitivity 86.7% and specificity 80%) and IL-13 concentration higher than 20.17 pg/ 
/mL (with sensitivity 100% and specificity 76.7%) in EBC in children with wheezing recurrence can be considered as a possible 
predictor of asthma development.
Conclusions: The concentration of the anti-inflammatory cytokines IL-4 and IL-13 were significantly increased in children with 
recurrent wheezing and the highest rates were found in asthma developing children. The concentrations of IL-4 and IL-13 in chil-
dren with wheezing can be considered as a possible predictor of asthma development.
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Introduction 
Asthma is one of the most common chronic 
diseases in children and young adults [1–5]. 
The number of severe and uncontrolled forms of 
asthma has increased, leading to greater disability 
and mortality among patients [1–2]. The debut of 
the disease takes place in childhood [3–5]. Accu-
rate diagnosis of asthma in this age cohort may 
represent a significant clinical challenge [1, 3, 6]. 
Firstly, the clinical signs of wheezing in children 
can be caused by many diseases, among which, 
besides asthma, there are hereditary and birth 
defects with metabolic processes, pathology of the 
gastroesophageal zone, congenital and acquired 
defects of the heart and main vessels and many 
others that should be included in the differential 
diagnostics [3–5, 7]. Secondly, in children under 
6 years of age, there are limitations in the study of 
lung function. Therefore, in this cohort, diagnosis 
is based mainly on clinical and anamnestic data 
[6–8]. So, the global medical problem is to expand 
the diagnostic possibilities of early detection of 
asthma in children. 
The pathogenesis of the disease, namely 
chronic inflammation, is a systemic process, but 
it damages mainly the respiratory tract [8, 9]. At 
the beginning of the formation of inflammation, 
the mechanisms do not depend on the type of the 
damage (allergic, infectious, etc.) and have gene-
ral signs of action of cytokine complexes [10–13]. 
Several proinflammatory (IL1, IL-6, IL-8, TNF-α, 
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GM-CSF) and anti-inflammatory cytokines (IL-4, 
IL-10, IL-13, TGF-b) are synthesized [11–13]. It 
is known that IL-4 function is to induce incre-
ased concentration of IgE, and IL-13 is a unique, 
Th2-linked, cytokine that interacts with B cells 
and thus regulates inflammatory and immune 
responses [14–16]. Recent studies have found 
an increase in serum concentration of these 
anti-inflammatory cytokines. They are not only 
able to induce the inflammatory process, but also 
support it, leading to a chronic activity. These 
interleukins that characterize chronic inflamma-
tion lead to airway remodeling and hyperplasia 
of the muscular system of the bronchopulmonary 
system [17]. Thus, it is advisable to study the 
concentration of these indicators directly in the 
inflammation locus. 
The study of mediators and markers of in-
flammation released by damage of the respira-
tory system is possible due to the procedure of 
bronchoalveolar lavage or induced sputum [18]. 
However, because of the fact that these studies 
are related to invasive intervention, they cannot 
be repeated in a short period of time, especially 
in pediatric patients. Considering non-invasive 
methods that can be used in children, and to be 
able to reflect the state of local inflammation 
of the respiratory system, the exhaled breath 
condensate (EBC) seems to be optimal option 
[18]. It is a promising source of biomarkers of 
lung disease. EBC represents a matrix in which 
biomarkers can be identified [18, 19]. Till date 
interleukins’ levels in EBC, especially in cohorts 
of young children have been rarely evaluated. In 
this study, we conducted clinical and progno-
stic evaluation of interleukin 4 and interleukin 
13 concentration in EBC children with recurrent 
wheezing episodes. 
Material and methods 
Study design 
This was a longitudinal cohort study of 
children with recurrent wheezing from February 
2015 to November 2019 who were treated at 
a children’s hospital. The study consisted of two 
stages. In the first phase (recruitment, February 
2015 — May 2015), among the 305 children who 
were admitted to the hospital with wheezing, 
126 children between the ages of 1.5 and 6, who 
met the inclusion criteria and did not fulfill 
exclusion criteria were included to the study. 
Inclusion criteria: signing informed consent by 
the patient’s parents; patient’s age from 1.5 to 
6 years; current wheezing episode at recruitment 
is third and more. Exclusion criteria: congenital 
and chronic cardiopulmonary or neurological 
disease; hereditary diseases that lead to changes 
in the functioning of the respiratory tract, inclu-
ding cystic fibrosis; proven immune deficiency; 
proven or suspected acute or chronic bacterial 
infection, including infection of the oral cavity 
and respiratory tract; suspected or confirmed 
gastroesophageal diseases; previous treatment 
with antileukotriene drugs or systemic corticoste-
roids. The patients underwent specific treatment 
according to accepted recommendations [20]. All 
study subjects underwent clinical medical histo-
ry review, physical examination and laboratory 
assessment. Children were also examined for 
IL-4 and IL-13 concentration in the exhaled bre-
ath condensate. The study of anti-inflammatory 
cytokines was conducted on the first day of the 
disease in the presence of clinical manifestations 
of wheezing. 
The control group comprised 25 healthy chil-
dren (of similar age/gender) without any  signs of 
chronic or acute diseases for the previous three 
months, presented to Hospital for routine health 
control or vaccination. The parents of all patients 
and controls were informed about the study objec-
tives and written informed consent was obtained 
before inclusion in the study. 
Second stage (follow-up, May 2015—Sep-
tember 2019). The patients were called for re-e-
xamination at the age of 5–6 years. The inc-
lusion and exclusion criteria in the study were 
re-evaluated. In the second stage, 96 children 
met the inclusion criteria and did not satisfy 
exclusion criteria. Anamnestic data for this pe-
riod were studied. An examination was carried 
out to verify the diagnosis of asthma at the time 
of re-examination. The diagnosis was based on 
the GINA 2019 criteria and included symptoms 
(cough and wheezing) for more than 10 days 
during the upper respiratory tract infection, 
more than 3 episodes of wheezing per year, the 
child coughed between episodes, and there were 
present atopic dermatitis or food allergy history 
or family history of asthma [20]. An objective as-
sessment of the severity of respiratory failure and 
differential diagnosis of obstructive and possible 
restrictive respiratory disorders were performed. 
The patients were divided into groups depending 
on the asthma diagnosed during this period or 
diagnosed during the visit. The first group inc-
luded 81 transient wheezing (TW) children who 
stopped wheezing symptom at follow-up. The 
second group included 15 patients with doctor-
diagnosed asthma (DDA). 
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Exhaled breath condensate: 
technical and diagnostic aspects 
The device for EBC receiving was designed 
using a portable glass tube in accordance with 
material collection standards. The glass tube was 
cooled, surrounded by a mixture of refrigerants 
to obtain a temperature that reached from -5°C to 
-10°C. There, exhaled air in the form of droplets 
was converted to EBC [18, 21]. After collection, 
the glass tube was detached, and the sample was 
stored immediately at -70° C. The device has 
a manual control of condensing temperature and 
cleaning requirements of the tool between con-
sequent trials. All collections were done between 
8:30 and 09:30 a.m. The subjects wore a nose 
clip, which prevented contamination of the ma-
terial with excretions from the nasal mucosa, and 
prevented the possibility of inhaling or exhaling 
through the nasal cavity. For children over three 
years of age, condensate was collected through 
systems with a single-use mouthpiece that was 
connected to a one-way exhalation valve to pre-
vent the effects of inhaling the condensate. For 
subjects younger than two years, an exhalation 
valve with an inhalation mask was used. 
Measurement of IL-4 and IL-13 
in exhaled breath condensate
IL-4 in EBC were analyzed by the ELISA 
technique using commercial kits (Human IL-4, 
“Vector Best Ukraine”, catalog number: A-8754), 
and IL-13 concentration were analyzed by the 
ELISA technique using commercial kits (Human 
IL-13, eBioscience (Bender MedSystems), catalog 
number: BMS231-3, USA) according to the ma-
nufacturer’s instructions. 
Statistical analysis 
All statistical analyses were performed using 
StatSoft STATISTICA Version 8 package program 
(Tulsa, OK) and MedCalc statistical Software Ver-
sion 17.2. Shapiro-Wilk’s test was used, and histo-
gram and q-q plots were examined to assess the 
normality. As the sample distribution was different 
from the normal, the median (Me) and the interqu-
artile range were determined (Lq - lower quartile; 
Uq - upper quartile). Fisher’s exact test, χ2 was used 
to calculate two relative indicators. Nonparametric 
Mann-Whitney test (MW) was applied to compare 
the two samples and Wilcoxon (T) nonparame-
tric test was used to compare the two dependent 
samples. The difference between the two para-
meters was considered statistically significant at 
p < 0.05. The correlation between parameters was 
determined using the Spearman rank correlation 
analysis (r); p < 0.05 was considered to indicate 
a statistically significant difference. Receiver ope-
rating characteristic (ROC) curves were drawn for 
variables to determine the optimal «cut-off» values 
to predict an endpoint. The endpoint of this study is 
the formation of chronic inflammation in children 
with recurrent wheezing. The cut-off point of each 
variable and sensitivity, specificity, positive likeli-
hood ratio (+LR), negative likelihood ratio (LR) of 
this ”cut-off” point was obtained using the Youden 
index. To determine the most reliable screening tool 
among these four variables, pairwise comparison 
of these variables was performed by determining 
the differences between area under the curve using 
the Hanley and McNeil method.
Ethics approval and consent to participation 
The planned clinical studies were carried out 
after receiving approval by the local ethics com-
mittee (date: February 1, 2015; number: 2015/01) 
and were conducted in accordance with the 
principles of the Helsinki Declaration, amended 
in October 2013. 
Results
General information
Of the 96 children with recurrent wheezing 
enrolled to the study, the majority were diagnosed 
with transient wheezing (TW) (as they stopped 
wheezing at follow-up), and a minority develo-
ped asthma (DDA). These groups accounted for 
84.38% and 15.62%, respectively. No significant 
difference was found when comparing age and 
gender groups. Anamnestic factors such as pre-
gnancy, cesarean delivery, and frequent manife-
stations of viral infections of the upper respiratory 
tract, presence of pets, passive smoking were not 
statistically different between those groups. In 
regard of allergic history, atopic dermatitis, food 
allergy, allergic rhinitis, the presence of allergic 
diseases and asthma in relatives, wheezing in the 
first year of life were likely to be more frequent in 
patients with DDA. Elevated eosinophil level and 
high IgE level were also significantly increased 
in patients with DDA (Table 1). 
IL-4 and IL-13 concentration
IL-4 concentrations were significantly higher 
in DDA (21.13 pg/mL) and TW (13.86 pg/mL)  groups 
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as compared to healthy controls (3.37 pg/mL; 
p < 0.001), and the highest rates were observed 
in children with diagnosed asthma (p < 0.001, 
DDW vs TW, respectively) (Table 2). Similarly, 
IL-13 concentrations were significantly higher in 
DDA (26.13 pg/mL) and TW (18.3 pg/mL) groups 
as compared to healthy controls (16.35 pg/mL; 
p < 0.001), and the highest rates were observed 
in children with diagnosed asthma (p < 0.001, 
DDW vs TW, respectively).
Correlation between IL-4 and IL-13 parameters 
The correlation between IL-4 and IL-13 con-
centration of all children with recurrent wheezing 
was found (r = +0.37, p < 0.001). The relation-
ship between those biomarkers in children with 
DDA was r = +0.74, p < 0.001, and in TW cohort 
r = +0.17, p < 0.001. 
Prognostic criteria for IL-4 and IL-13 
To determine the prognostic significance of 
the concentration of IL-4 and IL-13, ROC curve 
analysis was performed. The relationship be-
tween cytokine level during the first episodes of 
wheezing and the development of asthma was 
determined. The cut-off value for the concentra-
tion of IL-4 higher than 18.45 pg/mL resulted in 
specificity of 80% and sensitivity of 86.7%, and 
for IL-13, concentration higher than 20.17 pg/mL 
resulted in specificity of 76.7% and sensitivity 
of 100% for the predefined endpoint, namely the 
formation of chronic asthma (Figure 1). 
Discussion 
This study found that among children with 
recurrent wheezing, a greater proportion of pa-
tients had transient wheezing and only 15.62% 
developed asthma during follow-up. There are 
many studies that describe the possible contribu-
ting factors in children with recurrent wheezing 
for formation of asthma. Several phenotypes are 
considered as the debut of the disease. The pro-
portion of such children ranges from 13% to 16% 
according to various sources [6, 22–24]. This fact 
has been confirmed in our study. 
In our study, an increased concentration of 
IL-4 in the exhaled breath condensate of children 
with recurrent wheezing in the onset of clinical 
manifestations was determined. The highest rates 
were found in children who developed asthma 
during the follow-up. IL-4 is known to stimulate 
IgE production, promote eosinophil accumulation 
in peripheral blood and tissues [14-17, 25–26]. 






Gender, M/F 48/33 10/5 p > 0.05
Age, years at recruitment Me (Lq; Uq) 2.58 (1.55; 4.10) 2.00 (1.50; 3.11) p > 0.05
Age, years at follow-up Me (Lq; Uq) 7.09 (6.00; 9.90) 6.50 (6.00; 7.80) p > 0.05
Caesarean section 42.2% (35/81) 33.3% (5/15) p > 0.05
Gestation period 39 (35; 41) 38 (35; 40) p > 0.05
Presence of atopic dermatitis in children 39.5% (32/81) 73.3% (11/15) p = 0.0227
Presence of food allergy in children 35.8% (29/81) 80.0% (12/15) p = 0.0033
Present of allergic rhinitis in children 2.5% (2/81) 46.7% (7/15) p < 0.001
Present of allergic disease in relatives 3.7% (3/81) 60.0% (9/15) P < 0.001
Presence of asthma in relatives 2.5% (2/81) 53.3% (8/15) P < 0.001
Onset of wheezing of the first year of life 48.1% (39/81) 80.0% (12/15) p = 0.0267
Current wheezing episode at recruitment 4 (3; 4) 5 (3;5) p > 0.05
Current pet ownership at recruitment 27.2% (22/81) 26.7% (4/15) p > 0.05
Repeated upper respiratory tract infection 85.2% (69/81) 80.0% (12/15) p > 0.05
Passive smoking 27.2% (22/81) 26.7% (4/15) p > 0.05
High eosinophil blood 8.7% (7/81) 60.0% (9/15) p < 0.001
IgE increase, IU/ml 25.9% (21/81) 86.7% (13/15) p < 0.001
DDA — doctor diagnosed asthma; TW — transient wheeze
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As a result, IL-4 is regarded as a cytokine that 
has a direct effect on the development of allergic 
inflammation [14–17]. An increased concentra-
tion of this cytokine has been shown to indicate 
the presence of allergic inflammation in pa-
tients. There are studies demonstrating changes 
in serum IL-4 concentration in atopic dermatitis 
in children [25], adults, and adolescents with 
asthma [14, 17]. Recent researches have proved 
that IL-4 concentration increase in the EBC of 
adult asthma patients, and IL-4 is considered as 
a marker of chronic allergic inflammation [26]. 
In our study, children up to 6 years of age were 
examined, but IL-4 was also elevated, which was 
likely to indicate an allergic nature of inflamma-
tion of the bronchopulmonary system. An incre-
ased IL-4 concentration in the exhaled breath 
condensate can be considered as a manifestation 
of an active inflammatory process, directly in the 
inflammation locus. 
We found that in children with recurrent 
wheezing, in the onset of clinical manifestations, 
IL-13 concentration in exhaled breath condensate 
was also increased as compared to healthy con-
trols. The highest levels were found in children 
who developed asthma. IL-13 is a Th2-linked cy-
tokine and regulates the body’s inflammatory and 
immune responses. It stimulates the production 
Figure 1. ROC curves for IL-4 and IL-13 as a biomarker of asthma development in children with wheezing episode












KW by Ranks: H = 41.38; p < 0.001









KW by Ranks: H = 29.91; p < 0.001
MW: p1–2 < 0.001;         p1- control = 0.0229;       p2- control < 0.001.
DDA — doctor diagnosed asthma; KW — Kruskal-Wallis test; Me (Lq; Uq) — median (lower quartile; upper quartile); MW— Mann-Whitney test; p significant with 
the Bonferroni correction; TW — transient wheeze
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of B cells and IgE, and inhibits the formation of 
inflammatory cytokines [14–17]. Recent studies 
have reported an increased IL-13 concentration 
in serum in atopic diseases in children [17, 25]. 
There are data that confirmed an elevated IL-
13 concentration in the serum in adolescents 
and adults asthma [14, 17]. These studies suggest 
that changes in the concentration of this cytokine 
indicate the presence of allergic inflammation. We 
have also regarded it as a manifestation of allergic 
inflammation, as well as activity of the process 
in the respiratory system, taking into account the 
detection of indicators in the locus of damage. 
Our study evaluated the relationship between 
IL-4 and IL-13 in EBC children less than 6 years 
of age and established direct correlation between 
indicators. Similarly, significant correlation was 
found in children who developed asthma. The 
correlations of IL-13 and IL-4 were made taking 
into account the presence of similar pathways that 
are involved in the synthesis of IgE, activation 
of eosinophils, mucus secretion [14-16]. Recent 
studies have demonstrated these relationships 
in adult patients with allergic airway disease 
[17, 25], where IL-4 has been identified as the 
first cytokine to be produced by mast cells and 
responsible for promoting the production of IL-
13 of mast cells [15]. Our study confirms the rela-
tionship between these cytokines in the presence 
of allergic inflammation in children. 
The ROC analysis determined the predictive 
concentrations of IL-4 and IL-13 for development 
of asthma in children with wheezes. The criterion 
of IL-4 > 18.45 pg/mL and IL-13 > 20.17 pg/mL 
were found to have prognostic significance, with 
high specificity and sensitivity rates in asthma 
formation in children with recurrent wheezing. 
Non-invasive techniques are used to investiga-
te the health status of adults and children. There 
are several non-invasive techniques for the deter-
mination of respiratory gases in exhaled air and 
compounds dissolved in exhaled lung secretion. 
There are studies using Electronic Noses (E-noses) 
that can play a potential role in the screening and 
analysis of various respiratory and systemic dise-
ases [27–29]. The EBC was chosen for our study.
This study has several limitations. Firstly, abo-
ut 45% of children were with comorbid diseases, 
such as atopic dermatitis or food allergy, which 
may result in higher concentration of IL-4 and 
IL-13 both in serum and EBC. Thus, the concen-
tration of these cytokines obtained in children 
with asthma could have higher rates due to con-
comitant allergic diseases [14, 25]. However, there 
is no evidence-based data that concentration of 
IL-4 or IL-13 can increase in EBC in children with 
comorbid allergic diseases. Substances in the EBC 
are in large dilution, as the excretory fluid covers 
both the alveolar epithelial layer and the mucous 
layer of the respiratory tract. There is no existing 
model that allows collecting all the exhalation, 
since the loss of moisture depends on the humidity 
and temperature of the environment. These factors 
are likely to have an influence on the obtained 
results [18–19, 21, 26]. Another limitation of the 
study is that asthma is a heterogeneous disease 
and has many phenotypes [9, 22, 30–31]. There are 
types that have neutrophil and paucigranulocytic 
phenotype in their mechanism of development. 
The most common is the eosinophilic type of 
inflammation, which is associated with eosino-
philic cellular infiltration and thickening of the 
basement membrane area. The performed studies 
and the selected cytokines reflect just this type of 
inflammation. This study was conducted taking 
into account only the eosinophilic phenotype, 
which is the most frequent in children.
In conclusion, among patients presenting 
with recurrent wheezing, approximately in eve-
ry sixth child, the disease has been transformed 
into asthma. The concentrations of the IL-4 and 
IL-13 in exhaled breath condensate were signifi-
cantly increased in children with manifestation 
of wheezing, and the highest rates were found in 
asthma developing children. Both cytokines are 
involved in the regulation of allergic inflamma-
tory processes in the body, and have an influence 
on the respiratory tract, as it was detected basing 
on IL-4 and IL-13 concentration in the exhaled 
breath condensate. IL-4 concentration higher than 
18.45 pg/mL and IL-13 concentration higher than 
20.17 pg/mL in exhaled breath condensate in chil-
dren with wheezing recurrence can be considered 
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